Sina Cathérine Rosenkranz

Sina Cathérine Rosenkranz
University Medical Center Hamburg - Eppendorf · Institute of Neuroimmunology and Multiple Sclerosis Research (INIMS)

MD

About

43
Publications
8,167
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
259
Citations
Introduction
Sina C. Rosenkranz currently works as a postdoctoral researcher at the Institute of Neuroimmunology and Multiple Sclerosis (INIMS). Her work focuses on the role of mitochondria alterations during Multiple Sclerosis and the molecular basis of neuroprotective behavioural interventions, such as exercise and hypoxia.
Additional affiliations
March 2019 - June 2019
Massachusetts General Hospital
Position
  • PostDoc Position
January 2012 - present
University Medical Center Hamburg - Eppendorf
Position
  • PostDoc Position
July 2007 - December 2011
University Medical Center Hamburg - Eppendorf
Position
  • PhD Student
Education
October 2004 - November 2011

Publications

Publications (43)
Article
Full-text available
Although most of the progressive multifocal leukoencephalopathy (PML) cases in sarcoidosis patients are explained by the treatment with immunosuppressive drugs, PML is also reported in treatment-naive sarcoidosis patients, which implies a general predisposition of sarcoidosis patients for PML. Indeed, it was shown that active sarcoidosis patients h...
Article
Background The human cytokine erythropoietin conveys neuroprotection in animal models but has shown ambiguous results in phase 2 clinical trials in patients with optic neuritis. We assessed the safety and efficacy of erythropoietin in patients with optic neuritis as a clinically isolated syndrome in a multicentre, prospective, randomised clinical t...
Article
Full-text available
Background: Walking disability is one of the most frequent and burdening symptoms of progressive multiple sclerosis (MS). Most of the exercise intervention studies that showed an improvement in mobility performance were conducted in low to moderately disabled relapsing–remitting MS patients with interventions using the legs. However, MS patients wi...
Article
Full-text available
While transcripts of neuronal mitochondrial genes are strongly suppressed in central nervous system inflammation, it is unknown whether this results in mitochondrial dysfunction and whether an increase of mitochondrial function can rescue neurodegeneration. Here we show that predominantly genes of the electron transport chain are suppressed in infl...
Article
Full-text available
Background: Progressive multifocal leukoencephalopathy (PML) caused by JCV is a rare but frequently fatal disease of the central nervous system, usually affecting immunocompromised individuals. Our study aims to expand the data on patient characteristics, diagnosis, clinical course, possible PML-directed treatment, and outcome of patients with PML...
Article
Full-text available
Background Impairment of visual function is one of the major symptoms of people with multiple sclerosis (pwMS). A multitude of disease effects including inflammation and neurodegeneration lead to structural impairment in the visual system. However, the gold standard of disability quantification, the expanded disability status scale (EDSS), relies o...
Article
Background: Instrumented assessment of motor symptoms has emerged as a promising extension to the clinical assessment of several movement disorders. The use of mobile and inexpensive technologies such as some markerless motion capture technologies is especially promising for large-scale application but has not transitioned into clinical routine to...
Preprint
BACKGROUND Instrumented assessment of motor symptoms has emerged as a promising extension to the clinical assessment of several movement disorders. The use of mobile and inexpensive technologies such as some markerless motion capture technologies is especially promising for large-scale application but has not transitioned into clinical routine to d...
Article
Background: Physical activity (PA) has beneficial effects on many disease related symptoms in people with multiple sclerosis (pwMS). Physical parameters - such as muscle strength, endurance, and balance - as well as fatigue, depression and neurocognitive functioning, can be positively influenced by regular PA. Nevertheless, pwMS are less physically...
Article
Full-text available
Blood-brain barrier (BBB) dysfunction is critically involved in determining the extent of several central nervous systems (CNS) pathologies and here in particular neuroinflammatory conditions. Inhibiting BBB breakdown could reduce the level of vasogenic edema and the number of immune cells invading the CNS, thereby counteracting neuronal injury. Tr...
Preprint
Full-text available
Central nervous system (CNS) inflammation in multiple sclerosis (MS) drives neuro-axonal loss resulting in irreversible disability. While transcripts of mitochondrial genes are strongly suppressed in neurons during CNS inflammation, it is unknown whether this results in mitochondrial dysfunction and whether interventions that increase mitochondrial...
Article
Full-text available
Nicotinic acid adenine dinucleotide phosphate (NAADP) is a second messenger that evokes calcium release from intracellular organelles by the engagement of calcium release channels, including members of the Transient Receptor Potential (TRP) family, such as TRPML1, the (structurally) related Two Pore Channel type 1 (TPC1) and TPC2 channels as well a...
Article
Full-text available
Exercise as a subset of physical activity is a cornerstone in the management of multiple sclerosis (MS) based on its pleotropic effects. There is an exponential increase in the quantity of research on exercise in MS, yet a number of barriers associated with study content and quality hamper rapid progress in the field. To address these barriers and...
Article
Full-text available
Identifying T cell clones associated with human autoimmunity has remained challenging. Intriguingly, many autoimmune diseases, including multiple sclerosis (MS), show strongly diminished activity during pregnancy, providing a unique research paradigm to explore dynamics of immune repertoire changes during active and inactive disease. Here, we chara...
Article
Full-text available
Multiple sclerosis (MS) is characterized by inflammatory insults that drive neuroaxonal injury. However, knowledge about neuron-intrinsic responses to inflammation is limited. By leveraging neuron-specific messenger RNA profiling, we found that neuroinflammation leads to induction and toxic accumulation of the synaptic protein bassoon (Bsn) in the...
Article
Full-text available
Background Only few aerobic exercise intervention trials specifically targeting cognitive functioning have been performed in multiple sclerosis. Objective and Methods This randomized controlled trial with 34 patients in the intervention group (IG) (mean: 38.2 years (±9.6)) and 34 patients in the control group (CG) (mean: 39.6 years (±9.7)) aimed t...
Preprint
Full-text available
Background: Only few aerobic exercise intervention trials specifically targeting cognitive functioning have been performed in MS. Objective and methods: This randomized controlled trial aimed to determine the effects of aerobic exercise on cognition in relapsing-remitting MS. The primary outcome was verbal memory (Verbal learning and memory test, V...
Article
Full-text available
Primary progressive multiple sclerosis (PPMS) shows a highly variable disease progression with poor prognosis and a characteristic accumulation of disabilities in patients. These hallmarks of PPMS make it difficult to diagnose and currently impossible to efficiently treat. This study aimed to identify plasma metabolite profiles that allow diagnosis...
Data
Workflow and summary of metabolomic profiling. (A) General workflow in data analysis. (B) Pie chart illustrating the percentage of putatively identified metabolites from each metabolite class, classified according to KEGG, Lipidmaps and HMDB. In total 534 metabolites were analysed. (C) PLS-DA scores plot of all 534 metabolites in HC cohort A (n = 1...
Data
Linear model fit of PPMS marker levels and age of all analyzed individuals in PPMS cohorts A and B. Utilized linear model to fit correlation between PPMS marker levels and ageing. Black: Linear model for all data points, light red: linear model for HC cohort A, green: linear model for HC cohort B, blue: linear model for PPMS cohort A, purple: linea...
Data
Inter-cohort dependencies determined by chi-square test for gender and one-way ANOVA for age, EDSS and disease duration (DD). Comparisons with significant p-values (p-value < 0.05) are highlighted in bold red.
Data
PPMS marker levels and sex dependency in all individuals analyzed. Utilized one way ANOVA with Tukey’s post hoc test to compute differences between PPMS marker levels and sex in all groups. ∗Metabolites with significantly different levels between males and females (p-value < 0.05), ∗∗Metabolites with significantly different levels between males and...
Data
Linear model fit of PPMS marker levels and age of all analyzed individuals in the RRMS cohort. Utilized linear model to fit correlation between PPMS marker levels and ageing. Black: Linear model for all data points, green: linear model for HC, orange: linear model for RRMS. Grey areas around the lines indicate the 0.95 confidence interval. Metaboli...
Data
Cohorts. Patient information from investigated RRMS, PPMS, PD cohorts including age and gender. A disease duration of 0 corresponds to less than 1 year (∗.xlsx file).
Data
Plasma metabolites identified in PPMS cohorts A and B (∗.xlsx file).
Data
Model parameters for the tested models and their corresponding p-values after sample-label permutation test.
Data
Metabolites with significant changes between HC and PPMS patients (A and B cohorts) their corresponding AUC values and VIP score ranks for component 1 and 2. Univariate AUCs and 95% CI (500 bootstrapping) calculated using MetaboAnalyst.
Data
PPMS marker measured in RRMS, intensity levels in the RRMS cohort. P-values determined by Welch’s t-test, p-value adjustment for multiple comparison using Benjamini and Hochberg (FDR) adjustment (∗.xlsx file).
Data
Extracted ion chromatograms of metabolites contributing to the specific PPMS signature.
Data
Linear model fit of PPMS marker levels and age of all individuals analyzed in the PD cohort. Utilized linear model to fit correlation between PPMS marker levels and ageing. Black: Linear model for all data points, green: linear model for HC, purple: linear model for PD. Grey areas around the lines indicate the 0.95 confidence interval. Metabolites...
Data
PPMS marker in PPMS patients compared to RRMS and PD patients. First p-value is determined by one-way ANOVA with Tukey’s post hoc with correction for multiple testing per metabolite. Metabolites with p-values < 0.05 are highlighted in bold green. Second p-value has been corrected (FDR) for all comparison including all metabolites.
Data
Pathway analysis of identified changes in PPMS patients compared to healthy controls (HC). Pathway information retrieved from KEGG. Significantly altered metabolites are highlighted in dark red rectangles including the corresponding KEGG ID. Grey font indicates involved enzymes, dashed grey line indicates additional reactions which are not displaye...
Data
MS/MS fragments used for PPMS marker identification. Identities confirmed by available authentic standards (validation level 1). MS/MS spectra were matched against online databases such as Metlin and MassBank (validation level 2) or against in silico fragmentation spectra (validation level 3) retrieved from Metfrag, CFM-ID and/or CSI:FingerID with...
Data
PPMS marker measured in PD, intensity levels in the PD cohort. P-values determined by Welch’s t-test, p-value adjustment for multiple comparison using Benjamini and Hochberg (FDR) adjustment (∗.xlsx file).
Data
Metabolite levels with significant changes between HC and PPMS patients measured in the longitudinal PPMS cohort (∗.xlsx file).
Article
Background: Fingolimod can lead to increased risk of cardiac events such as bradycardia or atrioventricular (AV) block. Objective: Evaluate acute and long-term effects of fingolimod on heart rhythm (HR), heart rate variability (HRV) and development of AV-blocks. Methods: In 64 patients with relapsing-remitting multiple sclerosis Holter ECG mon...
Article
Background: New diagnostic criteria of Multiple Sclerosis (MS) increase the number of patients being diagnosed with MS while a substantial part might not convert to clinically definite MS (CDMS). Objective: Diagnostic accuracy of the McDonald 2005 and 2010 criteria for conversion to CDMS was evaluated in an unselected cohort of patients in whom...
Article
Full-text available
Neuromyelitis optica spectrum disorder (NMOSD) is a rare relapsing autoimmune demyelinating disease of the CNS that predominantly affects the optic nerves and the spinal cord.¹ Because of the severity and poor recovery of attacks, aggressive immunosuppressive agents are used early in the clinical course to reduce relapse frequency. Apart from class...
Article
Background: Clinical studies have suggested beneficial effects of exercise on cognitive function in ageing adults and neurodegenerative diseases such as dementia. Recent work indicates the same for progressive multiple sclerosis (MS), an inflammatory and degenerative disease of the central nervous system (CNS). The biological pathways associated w...
Article
Full-text available
Die Inzidenz von Antikörper-assoziierten Enzephalitiden hat in den letzten Jahren stetig zugenommen. Dabei ist es wichtig, zwischen Antikörpern, die gegen intrazelluläre Proteine gerichtet sind und Antikörpern gegen neuronale Oberflächenproteine zu differenzieren, da sich die damit assoziierten Enzephalitiden sowohl in der Pathogenese als auch der...
Article
Full-text available
Alzheimer's disease (AD) is the most common form of dementia in the elderly with progressive cognitive decline and memory loss. According to the amyloid-hypothesis, AD is caused by generation and subsequent cerebral deposition of β-amyloid (Aβ). Aβ is generated through sequential cleavage of the transmembrane Amyloid-Precursor-Protein (APP) by two...

Network

Cited By

Projects

Projects (6)
Archived project
New targets in Alzheimer's therapy
Project
Analysis of new biomarkers in MS
Archived project
Decipher if TRPV4 KO can be protective in neuroinflammatory conditions